Heart failure & cardiomyopathies
Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF
Authors' conclusion
Dapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.
Study context
- Population
- Adults with heart failure (HF), NYHA class ≥II, elevated natriuretic peptides, ejection fraction (EF) <40% (DEFINE-HF) or >45% (PRESERVED-HF); median estimated glomerular filtration rate (eGFR) 59 (46, 77) mL/min/1.73 m²583 (99.3%) with baseline eGFR
- Comparison
- Dapagliflozin vs placebo, by baseline eGFR
- Outcome
- Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
- Follow-up
- 12 weeks
Methodological detailsdouble-blind, multicentre, subgroup analysis by eGFR, DEFINE-HF n = 236; PRESERVED-HF n = 324
- Double-blind
- Multicentre
- Subgroup analysis by eGFR
- DEFINE-HF n = 236; PRESERVED-HF n = 324
Pooled result
As reported in the abstract
KCCQ-CSS by baseline eGFR
- eGFR ≥ 60
- placebo-adjusted difference +6.0 points (95% CI 2.4–9.7); P = 0.001
- eGFR < 60
- placebo-adjusted difference +4.1 points (95% CI 0.5–7.7); P = 0.025
- Overall
- placebo-adjusted difference +5.0 points (95% CI 2.6–7.5); P < 0.001
- Benefit robust across eGFR modelled as continuous variable
- P for interaction = 0.48
Original publication
Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF. ESC Heart Fail. Published 24 December 2024. doi:10.
Summarised from the published abstract; every number is checked against it